Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1295Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 20-33

Systematic literature review to evaluate and characterize the health economics and outcomes research studies in India


1 Associate Medical Director, Oncology, Asia Medical Sciences Group, Quintiles Research (India) Private Limited (QRPL), New Delhi, India
2 Head, Knowledge Services, Capita India Private Limited, Mumbai, Maharashtra, India

Correspondence Address:
Divya Mishra
Associate Director, Medical-Oncology, Asia Medical Sciences, Quintiles, Regus Business, Centre, Level 12, Building 8, C DLF Cybercity, Phase 2, Gurgaon -122002
India
Login to access the Email id

Source of Support: This study was supported by Pfizer India Private Limited, Mumbai, India. The corresponding author was employed with Pfizer at the time of conduct and analysis of this study. Figures in editable file are uploaded on the site, Conflict of Interest: None


DOI: 10.4103/2229-3485.148802

Rights and Permissions

Aim: This systematic literature review was conducted to identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in India. Materials and Methods: Studies published in English language between 1999 and 2012 were retrieved from Embase and PubMed databases using relevant search strategies. Two researchers independently reviewed the studies as per Cochrane methodology; information on the type of research and the outcomes were extracted. Quality of reporting was assessed for model-based health economic studies using a published 100-point Quality of Health Economic Studies (QHES) instrument. Results: Of 546 studies screened, 132 were included in the review. The broad study categories were cost-effectiveness analyses [(CEA) 54 studies], cost analyses (19 studies), and burden of illness [(BOI) 18 studies]. The outcomes evaluated were direct and indirect costs, and incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and disability-adjusted life years (DALYs). Direct medical costs assessed cost of medicines, monitoring costs, consultation and hospital charges, along with direct non-medical costs (travel and food for patients and care givers). Loss of productivity and loss of income of patients and care givers were identified as the components of indirect cost. Overall, 33 studies assessed the quality of life (QoL), and the WHO Quality of Life-BREF (WHOQOL-BREF) was the most commonly used instrument. Quality assessment for modeling studies showed that most studies were of high quality [mean (range) QHES score to be 75.5 (34-93)]. Conclusions: This review identified various patterns of pharmacoeconomic studies and good-quality CEA studies. However, there is a need for better assessment of utilization of healthcare resources in India.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2349    
    Printed44    
    Emailed0    
    PDF Downloaded434    
    Comments [Add]    
    Cited by others 3    

Recommend this journal